The Medical Institution for Clinical Trials of Shanghai Mental Health Center (SMHC) sticks to the value of ”Safety Based, Quality Driven“focusing continually on capacity development and quality awareness. The Medical Institution for Clinical Trials is the largest psychiatry institution with experience of leading or participating in all kinds of drug clinical trials, covering phases IIV both at home and abroad. Totally 179 clinical trials of psychotropic drugs include antidepressants, antipsychotics, anti-anxiety agents, sedative hypnotics, nootropics, mood stabilizers, psychotropic drugs for children and adolescents, detoxification drugs and antialcoholics have been carried out. So far, the Medical Institution for Clinical Trials has already been leading or participating in 18 clinical trials of first-class new drugs. Among these studies, Medical Institution fbr Clinical Trials was in charge of two pivotal clinical trials for FDA NDA. In the past five years, the institution has conducted 11 multi-center clinical trials of innovative psychotropic drugs in China. For example, GV-971, a unique new compound in the world fbr the past two decades, is expected to be approved for the treatment of Alzheimer's Disease.